Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-095018
Filing Date
2025-04-25
Accepted
2025-04-25 07:57:02
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A d89310ddefa14a.htm DEFA14A 11831
2 GRAPHIC g89310g02g02.jpg GRAPHIC 377736
3 GRAPHIC g89310g03g03.jpg GRAPHIC 367786
  Complete submission text file 0001193125-25-095018.txt   1040354
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36483 | Film No.: 25870022
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)